Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Chemo in Metastatic Pancreatic Cancer
NCT04181645Phase 1Completed
- Sponsor
- Renji Hospital
- Start
- Jun 2019
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camrelizumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Renji Hospital. Primary endpoint: Objective Response Rate by Independent Review Committee at 2 years. Started Jun 2019; status: completed.
02
Drugs
camrelizumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04181645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04181645.